Publications & Reports

Patterns of, and Factors Associated With, Illicit Pharmaceutical Opioid Analgesic Use in a Prospective Cohort of People Who Inject Drugs in Melbourne, Australia.

Horyniak D, Agius PA, Degenhardt L, Reddel S, Higgs P, Aitken C, Stoové M, Dietze P
a Centre for Population Health, Burnet Institute , Melbourne , Victoria , Australia.

Abstract

BACKGROUND: People who inject drugs (PWID) are a key population engaging in pharmaceutical opioid analgesic (PO) use, yet little is known about patterns of illicit PO use among this group. OBJECTIVES: The aims of this research were to measure the prevalence and frequency of lifetime and past-month illicit PO use and injection in a sample of regular PWID, to examine patterns of past-month illicit PO use within individuals over time, and to identify factors independently associated with past-month illicit PO use. METHODS: Data were drawn from a prospective cohort study of regular PWID (N = 666) in Melbourne, Australia. Data from five waves of annual data collection (including baseline) were analyzed descriptively and using generalized estimating equations (GEE). RESULTS: At baseline, 59% of participants reported lifetime illicit PO use and 20% reported past-month use, predominantly through injecting. Most illicit PO users at baseline transitioned to nonuse of illicit POs across the study period. In multivariable GEE analysis, factors associated with past-month illicit PO use included past-year arrest [adjusted odds ratio (AOR): 1.39], opioids other than heroin as drug of choice (AOR: 5.14), experiencing poorer physical health (AOR: 0.98) and a range of other drug use variables. CONCLUSIONS: We found little evidence of ongoing illicit PO use among those followed up, with illicit PO use linked to polydrug use more broadly. Nonetheless, trends in illicit PO use among PWID should continue to be monitored and harm reduction interventions implemented to reduce the associated public health risks.

Link to publisher’s web site

This work was supported by the Colonial Foundation Trust and the Australian National Health and Medical Research Council [Grant 545891]. DH receives support from the Australian Government through an Australian Postgraduate Award and through the NHMRC Centre for Research Excellence into Injecting Drug Use (CREIDU). LD is supported by an NHMRC Principal Research Fellowship (#1041742). PH is supported by a Curtin University Research Fellowship. PA and CA are supported by the Burnet Institute. MS is supported by CREIDU. PD is supported by an ARC Future Fellowship. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program. The National Drug and Alcohol Research Centre at the University of New South Wales and the National Drug Research Institute at Curtin University are supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund.

Publication

  • Journal: Substance Use & Misuse
  • Published: 17/11/2015
  • Volume: 50
  • Issue: 13
  • Pagination: 1650-1659

Authors

Program

Health Issue